Adverse effects: Extrapyramidal symptoms (Simpson‐Angus) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group B antipsychotic drugs: olanzapine + supportive intervention changes prodromal symptoms: transition to psychosis Endpoint data, (events)… compared with placebo + supportive intervention (very low certainty).
1 finding from 1 review
Global effect: 1a. Medium‐term ‐ Average end point score on various outcomes ‐ CGI‐severity (low = favourable) ( · people in the prodromal stage of psychosis
1 finding from 1 review
Mental state: psychosis risk symptoms SOPS total (higher score = worse, scale from: 0‐114) · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Weight gain · people in the prodromal stage of psychosis
1 finding from 1 review
Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction and acceptability of treatment (medium term) ‐ leaving the study early · people in the prodromal stage of psychosis
It is very uncertain whether group B antipsychotic drugs: olanzapine + supportive intervention changes satisfaction with treatment: leaving the study early Endpoint data… compared with placebo + supportive intervention (very low certainty).
1 finding from 1 review
Depressive symptoms · treatment‐resistant depression in adults
2 findings from 1 review
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d to 60… showed no clear difference in dropouts compared with augmentation of current antidepressant (fluoxetine 20 mg/d to 60… (low certainty).
1 finding from 1 review
Proportions of participants responding to treatment ≥ 50% reduction in depression score from baseline to end of treatment. A larger RR indicates greater response to treatment in the SAMe group · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d to 60… showed no clear difference in response (≥50% reduction in MADRS score) compared with augmentation of current antidepressant (fluoxetine 20 mg/d to 60… (low certainty).
1 finding from 1 review
Remission ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found